Adynxx

Adynxx is a clinical-stage pharmaceutical company that is developing a potentially transformative technology platform for addressing pain at its molecular roots, treating the development of pain following a surgery or trauma and chronic pain syndromes.

Adynxx's pipeline of products includeincludes brivoligide, a Phase 2 drug candidate that is intended to address postoperative pain, and AYX2, a pre-clinical candidate that is intended to treat chronic syndromes of pain, includingpain—including inflammatory and neuropathic pain.

The company had announced its merger in October 2018, subject to closing, with Alliqua BioMedicalBioMedicalin April 2019, andwith the stockholders of Adynxx would be made to become the majority owners of Alliqua's outstanding common stock on a fully-diluted basis, and it would. beIt bringingbrought on board the post-op pain drug brivoligide, which is a drug candidate in development for the reduction of postoperative pain.

Adynxx is a clinical-stage pharmaceutical company that is developing a potentially transformative technology platform for addressing pain at its molecular roots, treating the development of pain following a surgery or trauma and chronic pain syndromes.

Adynxx's pipeline products include brivoligide, a Phase 2 drug candidate that is intended to address postoperative pain, and AYX2, a pre-clinical candidate that is intended to treat chronic syndromes of pain, including inflammatory and neuropathic pain.

The company had announced its merger in October 2018, subject to closing, with Alliqua BioMedical, and the stockholders of Adynxx would be made to become the majority owners of Alliqua's outstanding common stock on a fully-diluted basis, and it would be bringing on board brivoligide, which is a drug candidate in development for the reduction of postoperative pain.